BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bae A, Jung S, Lee J, Lee H, Park SG. Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy. Medicina 2022;58:155. [DOI: 10.3390/medicina58020155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Gao B, Wang Y, Lu S. Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma. Sci Rep 2023;13:1137. [PMID: 36670201 DOI: 10.1038/s41598-023-28436-z] [Reference Citation Analysis]
2 Jiang L, Li L, Liu Y, Lu L, Zhan M, Yuan S, Liu Y. Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma. Front Pharmacol 2023;14:1097277. [PMID: 36891274 DOI: 10.3389/fphar.2023.1097277] [Reference Citation Analysis]
3 Duan A, Li H, Yu W, Zhang Y, Yin L, Liao R. Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2. Journal of Oncology 2022;2022:1-17. [DOI: 10.1155/2022/4537343] [Reference Citation Analysis]
4 Wong YP, Che Abdul Aziz R, Noor Aizuddin A, Mohd Saleh MF, Mohd Arshad R, Tan GC. High EZH2 Protein Expression Is a Poor Prognostic Predictor in IDH1 R132H-Negative Gliomas. Diagnostics (Basel) 2022;12. [PMID: 36292072 DOI: 10.3390/diagnostics12102383] [Reference Citation Analysis]
5 Chen Z, Lin X, Wan Z, Xiao M, Ding C, Wan P, Li Q, Zheng S. High Expression of EZH2 Mediated by ncRNAs Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma. Genes 2022;13:876. [DOI: 10.3390/genes13050876] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]